FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
Cui YH, Kim H, Lee M, Yi JM, Kim RK, Uddin N, Yoo KC, Kang JH, Choi MY, Cha HJ, Kwon OS, Bae IH, Kim MJ, Kaushik N, Lee SJ.
Cui YH, et al. Among authors: kim h, kim rk, kim mj.
Oncogene. 2018 Oct;37(43):5794-5809. doi: 10.1038/s41388-018-0372-3. Epub 2018 Jul 4.
Oncogene. 2018.
PMID: 29973690